BRPI0923373B8 - composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação - Google Patents
composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinaçãoInfo
- Publication number
- BRPI0923373B8 BRPI0923373B8 BRPI0923373A BRPI0923373A BRPI0923373B8 BR PI0923373 B8 BRPI0923373 B8 BR PI0923373B8 BR PI0923373 A BRPI0923373 A BR PI0923373A BR PI0923373 A BRPI0923373 A BR PI0923373A BR PI0923373 B8 BRPI0923373 B8 BR PI0923373B8
- Authority
- BR
- Brazil
- Prior art keywords
- insulin
- combination
- compound
- formula
- triazine derivatives
- Prior art date
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 10
- 102000004877 Insulin Human genes 0.000 title abstract 5
- 108090001061 Insulin Proteins 0.000 title abstract 5
- 229940125396 insulin Drugs 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000003918 triazines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 3
- 206010022489 Insulin Resistance Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000004962 physiological condition Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
combinação de insulina com derivados de triazina e seu uso para tratar diabetes. a presente invenção refere-se a uma composição para uso como um medicamento compreendendo insulina em combinação com pelo menos um composto de fórmula (l) em que os radicais r1 to r6 têm o significados de acordo com a reivindicação 1, e/ou sais fisiologicamente aceitáveis dos mesmos. outro objetivo da invenção diz respeito a uma composição farmacêutica compreendendo como ingredientes ativos quantidades eficazes de insulina e pelo menos um composto de formula (l), junto com adjuvantes farmaceuticamente toleráveis, para o tratamento e/ou monitoramento profilático ou terapêutico de condições fisiológicas e/ou patológicas que estão associadas com resistência à insulina. a invenção também refere-se a uma embalagem farmacêutica compreendendo insulina em uma primeira unidade de dosagem e pelo menos um composto de fórmula (l) em uma segunda unidade de dosagem.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08021617 | 2008-12-12 | ||
| EP08021617.9 | 2008-12-12 | ||
| PCT/EP2009/008099 WO2010066326A1 (en) | 2008-12-12 | 2009-11-13 | Combination of insulin with triazine derivatives and its use for treating diabetes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BRPI0923373A2 BRPI0923373A2 (pt) | 2015-07-21 |
| BRPI0923373B1 BRPI0923373B1 (pt) | 2020-02-11 |
| BRPI0923373B8 true BRPI0923373B8 (pt) | 2021-05-25 |
Family
ID=41566311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0923373A BRPI0923373B8 (pt) | 2008-12-12 | 2009-11-13 | composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US8592370B2 (pt) |
| EP (1) | EP2355829B1 (pt) |
| JP (1) | JP5667985B2 (pt) |
| KR (1) | KR101623819B1 (pt) |
| CN (1) | CN102245185A (pt) |
| AR (1) | AR074555A1 (pt) |
| AU (1) | AU2009326604B2 (pt) |
| BR (1) | BRPI0923373B8 (pt) |
| CA (1) | CA2746479C (pt) |
| CY (1) | CY1115973T1 (pt) |
| DK (1) | DK2355829T3 (pt) |
| EA (1) | EA021395B1 (pt) |
| ES (1) | ES2530223T3 (pt) |
| HR (1) | HRP20150064T1 (pt) |
| IL (1) | IL213421A (pt) |
| MX (1) | MX2011006073A (pt) |
| PL (1) | PL2355829T3 (pt) |
| PT (1) | PT2355829E (pt) |
| SG (1) | SG171986A1 (pt) |
| SI (1) | SI2355829T1 (pt) |
| SM (1) | SMT201500032B (pt) |
| WO (1) | WO2010066326A1 (pt) |
| ZA (1) | ZA201105094B (pt) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2577930T3 (es) | 2010-06-09 | 2016-07-19 | Poxel | Derivados de triazina para retrasar el inicio de la diabetes tipo 1 |
| TWI436768B (zh) * | 2010-06-09 | 2014-05-11 | Poxel | 第２型糖尿病之治療 |
| SG11201403207WA (en) * | 2011-12-12 | 2014-09-26 | Melior Pharmaceuticals I Inc | Treatment of type i and type ii diabetes |
| BR112020006472A2 (pt) | 2017-10-02 | 2020-10-06 | Poxel | método para tratamento ou prevenção de insuficiência cardíaca com fração de ejeção preservada (icfep) |
| KR20200130281A (ko) | 2018-06-06 | 2020-11-18 | 메타반트 사이언시스 게엠베하 | 당뇨병과 만성 신장 질환을 갖는 대상체를 치료하는 방법 |
| KR20210003786A (ko) * | 2018-06-14 | 2021-01-12 | 폭셀 | 당뇨병의 치료에서 사용하기 위한 트리아진 유도체를 포함하는 필름 코팅정 |
| CN114945370A (zh) | 2019-12-13 | 2022-08-26 | 住友制药株式会社 | 具有优异可生产性和溶出性的小尺寸片剂 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3172814A (en) * | 1962-04-06 | 1965-03-09 | Jr Edgar A Ferguson | Oral blood sugar lowering compositions |
| FR2738741B1 (fr) * | 1995-09-19 | 1997-12-05 | Oreal | Composition pour la teinture des fibres keratiniques, contenant un antagoniste de substance p |
| FR2804113B1 (fr) * | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
| AU2002226633A1 (en) * | 2001-02-02 | 2002-08-12 | Pfizer Limited | Treatment of diabetes mellitus using vardenafil |
| DE10301788B4 (de) * | 2003-01-20 | 2005-08-25 | Aventis Pharma Deutschland Gmbh | Pharmazeutische Verwendung von Pyrimido[5,4-e][1,2,4]triazin-5,7-dionen |
| FR2896159B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. |
| FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
-
2009
- 2009-11-13 KR KR1020117016022A patent/KR101623819B1/ko active IP Right Grant
- 2009-11-13 SG SG2011041175A patent/SG171986A1/en unknown
- 2009-11-13 EP EP09756258.1A patent/EP2355829B1/en active Active
- 2009-11-13 BR BRPI0923373A patent/BRPI0923373B8/pt not_active IP Right Cessation
- 2009-11-13 DK DK09756258.1T patent/DK2355829T3/en active
- 2009-11-13 PT PT97562581T patent/PT2355829E/pt unknown
- 2009-11-13 CN CN2009801495028A patent/CN102245185A/zh active Pending
- 2009-11-13 ES ES09756258.1T patent/ES2530223T3/es active Active
- 2009-11-13 US US13/139,027 patent/US8592370B2/en active Active
- 2009-11-13 JP JP2011539914A patent/JP5667985B2/ja active Active
- 2009-11-13 WO PCT/EP2009/008099 patent/WO2010066326A1/en active Application Filing
- 2009-11-13 MX MX2011006073A patent/MX2011006073A/es active IP Right Grant
- 2009-11-13 SI SI200931123T patent/SI2355829T1/sl unknown
- 2009-11-13 AU AU2009326604A patent/AU2009326604B2/en not_active Ceased
- 2009-11-13 EA EA201100916A patent/EA021395B1/ru not_active IP Right Cessation
- 2009-11-13 CA CA2746479A patent/CA2746479C/en active Active
- 2009-11-13 PL PL09756258T patent/PL2355829T3/pl unknown
- 2009-12-09 AR ARP090104757A patent/AR074555A1/es unknown
-
2011
- 2011-06-06 IL IL213421A patent/IL213421A/en active IP Right Grant
- 2011-07-11 ZA ZA2011/05094A patent/ZA201105094B/en unknown
-
2013
- 2013-07-15 US US13/941,677 patent/US8980828B2/en active Active
-
2015
- 2015-01-19 HR HRP20150064AT patent/HRP20150064T1/hr unknown
- 2015-01-30 CY CY20151100101T patent/CY1115973T1/el unknown
- 2015-02-11 SM SM201500032T patent/SMT201500032B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0923373B8 (pt) | composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação | |
| BR112014012815A2 (pt) | derivados de trifluormetil-oxadiazol e uso dos mesmos no tratamento de doença | |
| BR112015029491A2 (pt) | derivados de imidazopirrolidinona e seu uso no tratamento de doença | |
| BR112015029512A2 (pt) | derivados de pirazolopirrolidina e seu uso no tratamento de doenças | |
| BR112015003188A2 (pt) | Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente | |
| BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| BRPI1015996B8 (pt) | composição oftálmica de múltiplas doses contendo complexos de borato-poliol. | |
| BR112015000136A2 (pt) | fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento | |
| BR112014032734A2 (pt) | derivados de pirrolidina e seu uso como moduladores da série de reação de complemento | |
| BRPI0514357A (pt) | combinações para o tratamento de doenças que envolvem a proliferação de células | |
| BR112013006344A2 (pt) | lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas | |
| CU20070203A7 (es) | Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| BR112022009805A2 (pt) | Derivados de piridopirimidinona como antagonistas de ahr | |
| BR112013026257A2 (pt) | derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes | |
| BRPI0708071A8 (pt) | Derivados de catecolamina deuterada e medicamentos compreendendo os ditos compostos | |
| BR112015029401A8 (pt) | derivados de pirazolo-pirrolidin-4-ona, seus usos, e composição e combinação farmacêuticas | |
| BR112015019039A8 (pt) | compostos antagonistas de integrina fluorados, composição farmacêutica compreendendo ditos compostos e uso destes para tratar ou prevenir uma doença ou condição mediada por uma av integrina | |
| BR112014006223A2 (pt) | 6-substituídas-3-(quinolin-6-iltio)-[1,2,4-triazol[4,3-a] piradinas como tirosina quinase c-met | |
| EA201401231A1 (ru) | Фармацевтические комбинации, предназначенные для лечения метаболических нарушений | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112012022074A2 (pt) | composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta | |
| BR112012020185A2 (pt) | uso de preparações de heparina oral para tratar doenças e afecções do trato urinário. | |
| BR112022022024A2 (pt) | Uso de um componente (i) em combinação com um componente (ii), composição farmacêutica, medicamento composto e kit | |
| DK1482919T3 (da) | Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: POXEL S.A.S. (FR) |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08G | Application fees: restoration [chapter 8.7 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 11/02/2020, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/11/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
| B21F | Lapse acc. art. 78, item iv - on non-payment of the annual fees in time |
Free format text: REFERENTE A 15A ANUIDADE. |